Ms. Anie Perrault is a lawyer by training (University of Ottawa – 1992; Barreau 1993) with more than 30 years of professional experience in the public and private sectors. Her career has focused on communications and public affairs related to genomic research and biotechnology and she has held several strategic positions at a national level in this field. She was Director General of BIOQuébec from 2013 to 2022 and Vice President, Communications of Genome Canada from 2001 to 2006.
Named Sun Life Leadership – Exceptional Woman finalist in the prestigious Les Mercuriades 2021 competition, Ms. Perrault is also an accredited mediator from the Institute of Mediation and Arbitration of Quebec. Ms. Perrault was a Member (administrative judge) of the Canadian Human Rights Tribunal from 2015 to 2021, and continues to act as a mediator there today.
In 2013, Ms. Perrault received the title of Certified Corporate Administrator from the College of Corporate Administrators at Laval University. She is president of the board of directors of Génome Québec. She has also served on the board of directors of ACCESSA since 2020. She was a member of the boards of the Jeanne-Mance Foundation from 2016 to 2022, Loto-Québec from 2011 to 2021 and the University of Sherbrooke from 2016 to 2019.
Day 1 Oct 28, 2025
4:10 pm
CASE STUDY
The Patented Medicine Prices Review Board’s (PMPRB) New Guidance for 2026
Hear the latest update on draft guidelines detailing the administrative process for recommending hearings on excessive drug pricing, to enhance transparency and procedural fairness in assessing whether a patented medicine’s price is excessive. Adopt best practices to:
- Learn directly from the PMPRB on how the draft guidelines and recommendations have been asserted.
- Gain clarity on the PMPRB’s interim guidance aimed at expediting price reviews and its impact on market entry timelines.
Master the roadmap for 2026 and beyond in PMPRB strategy to improve pricing processes and ensure timely market access for innovative medicines.
Day 2 Oct 29, 2025